NLS Pharmaceutics Ltd. (NASDAQ:NCEL – Get Free Report) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 41,855 shares, an increase of 1,000.6% from the November 30th total of 3,803 shares. Based on an average daily trading volume, of 132,110 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.1% of the company’s shares are sold short. Currently, 1.1% of the company’s shares are sold short. Based on an average daily trading volume, of 132,110 shares, the days-to-cover ratio is currently 0.3 days.
NLS Pharmaceutics Stock Performance
Shares of NCEL stock opened at $2.63 on Friday. The firm has a fifty day simple moving average of $5.73 and a 200-day simple moving average of $16.33. NLS Pharmaceutics has a twelve month low of $2.48 and a twelve month high of $33.70.
Analysts Set New Price Targets
Several equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of NLS Pharmaceutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NLS Pharmaceutics in a report on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.
NLS Pharmaceutics Company Profile
NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.
The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.
Featured Articles
- Five stocks we like better than NLS Pharmaceutics
- Washington prepares for war
- Do you know what Amazon is planning for January 1?
- Nvidia x 1,000,000
- $100 Trillion “AI Metal” Found in American Ghost Town
- Put $1,000 into this stock by Jan 1 [Not NVDA]
Receive News & Ratings for NLS Pharmaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NLS Pharmaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
